Details for Patent: 12,419,889
Which drugs does patent 12,419,889 protect, and when does it expire?
Patent 12,419,889 protects RHAPSIDO and is included in one NDA.
This patent has thirty patent family members in twenty-one countries.
Summary for Patent: 12,419,889
| Title: | Methods of treating chronic spontaneous urticaria using a bruton's tyrosine kinase inhibitor |
| Abstract: | The present disclosure relates to methods for treating Chronic Spontaneous Urticaria using a compound of Formula (I) or a pharmaceutically acceptable salt thereof. Also disclosed herein is a compound of Formula (I) or a pharmaceutically acceptable salt thereof, for treating Chronic Spontaneous Urticaria patients, as well as medicaments, dosing regimens, pharmaceutical formulations, dosage forms, and kits for use in the disclosed uses and methods. |
| Inventor(s): | Souvik BHATTACHARYA, Bruno BIETH, Maciej CABANSKI, Bruno CENNI, Stefan De Buck, Martin Kaul, Arvind KINHIKAR, Andrijana RADIVOJEVIC, Thomas Severin, Julian STORIM, Alessandra VITALITI GARAMI |
| Assignee: | Novartis AG |
| Application Number: | US17/612,778 |
|
Patent Claim Types: see list of patent claims | Use; Composition; Formulation; |
Drugs Protected by US Patent 12,419,889
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Novartis | RHAPSIDO | remibrutinib | TABLET;ORAL | 218436-001 | Sep 30, 2025 | RX | Yes | Yes | 12,419,889 | ⤷ Start Trial | TREATMENT OF CHRONIC SPONTANEOUS URTICARIA | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 12,419,889
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2020280272 | ⤷ Start Trial | |||
| Australia | 2025252618 | ⤷ Start Trial | |||
| Brazil | 112021022602 | ⤷ Start Trial | |||
| Canada | 3138081 | ⤷ Start Trial | |||
| Chile | 2021003032 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
